Literature DB >> 861137

Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution.

J K Aronson, D G Grahame-Smith.   

Abstract

1 In eighteen subjects receiving digoxin therapy the apparent volume of distribution (Vd) of the drug has been calculated. 2 For each subject the sensitivity of the 86Rb transport mechanism of his pre-treatment erythrocytes to in vitro inhibition by digoxin has been measured (IC50). 3 The Vd of digoxin correlates both with the age of the patients and with the IC50 of their pre-treatment erythrocytes. 4 The implications of these findings are discussed in terms of the possible determinants of the Vd of digoxin. 5 Digoxin requirements may be predictable before therapy commences if IC50 measurements are performed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 861137      PMCID: PMC1429023          DOI: 10.1111/j.1365-2125.1977.tb00698.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  ENZYMATIC BASIS FOR ACTIVE TRANSPORT OF NA+ AND K+ ACROSS CELL MEMBRANE.

Authors:  J C SKOU
Journal:  Physiol Rev       Date:  1965-07       Impact factor: 37.312

2.  New method for detecting and quantitating pharmacokinetic drug-drug interactions applied to ethanol-propranolol.

Authors:  J G Wagner; D J Weidler; Y J Lin
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-01

3.  Digoxin pharmacokinetics: role of renal failure in dosage regimen design.

Authors:  J R Koup; W J Jusko; C M Elwood; R K Kohli
Journal:  Clin Pharmacol Ther       Date:  1975-07       Impact factor: 6.875

4.  Induction of a ouabain-sensitive ATPase defect by uremic plasma.

Authors:  C H Cole; J W Balfe; L G Welt
Journal:  Trans Assoc Am Physicians       Date:  1968

5.  The biological availability of very rapidly dissolving digoxin tablets.

Authors:  T R Shaw; K Raymond; H Greenwood
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

6.  The bioavailability of other digoxin preparations compared with tablets.

Authors:  B F Johnson; C Bye; S Lader
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

7.  Decreased ouabain-sensitive adenosine triphosphatase activity in the erythrocyte membrame of patients with chronic renal disease.

Authors:  C H Cole
Journal:  Clin Sci Mol Med       Date:  1973-12

8.  Effect of age and cardiac glycosides on the activity of adenosine triphosphatase (ATPase) (EC 3.6.1.3) of red cell ghost membranes.

Authors:  D Platt; P Schoch
Journal:  Mech Ageing Dev       Date:  1974 Nov-Dec       Impact factor: 5.432

9.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

10.  Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.

Authors:  J K Aronson; D G Grahame-Smith; K F Hallis; A Hibble; F Wigley
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

View more
  13 in total

Review 1.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 2.  Indications for the measurement of plasma digoxin concentrations.

Authors:  J K Aronson
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

3.  Digoxin distribution between plasma and myocardium in hypoxic and non-hypoxic dogs.

Authors:  D W Harron; J G Swanton; P S Collier; A B Cullen
Journal:  Experientia       Date:  1982-07-15

Review 4.  Clinical pharmacokinetics of digoxin 1980.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  Loading dose of digoxin in renal failure.

Authors:  M H Gault; D N Churchill; J Kalra
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

6.  The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy.

Authors:  A R Ford; J K Aronson; D G Grahame-Smith; J A Rose
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

7.  The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.

Authors:  A R Ford; J K Aronson; D G Grahame-Smith; J G Carver
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

8.  Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response.

Authors:  J K Aronson; D G Grahame-Smith; K F Hallis; A Hibble; F Wigley
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

Review 9.  Physiological changes due to age. Implications for cardiovascular drug therapy.

Authors:  I Stolarek; P J Scott; F I Caird
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

10.  Relationship between dose and plasma level of digoxin and patient characteristics.

Authors:  N Heinz; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.